Selective metabolism of vincristine in vitro by CYP3A5

Drug Metabolism and Disposition

Volumn 34, Issue 8, 2006, Pages 1317-1327

  Dennison, Jennifer B ^a   Kulanthaivel, Palaniappan ^b   Barbuch, Robert J ^b   Renbarger, Jamie L ^a   Ehlhardt, William J ^b   Hall, Stephen D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; OXIDOREDUCTASE; PIPERIDINE; VINCRISTINE;

AEROBIC METABOLISM; ARTICLE; BIOTRANSFORMATION; CATALYSIS; DNA LIBRARY; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECTROSCOPY; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INSECTS; MICROSOMES; VINCRISTINE;

EID: 33746051348     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009902     Document Type: Article

References (35)

1. Ahn SH, Duffel MW, and Rosazza JP (1997) Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin. J Nat Prod 60:1125-1129.
2. Andriamialisoa RZ, Langlois N, Potier P, Chiaroni A, and Riche C (1978) The structure of catharanthinine: bisindolic "alkaloid" isolated from several Catharanthus species. Tetrahedron Lett 34:677-683.
3. Bohme A, Ganser A, and Hoelzer D (1995) Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 71:311-312.
4. Bradley SA, Krishnamurthy K, and Hu H (2005) Simplifying DOSY spectra with selective TOCSY edited preparation. J Magn Reson 172:110-117.
5. Chang Y, Moody DE, and McCance-Katz EF (2006) Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 34:440-448.
6. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Favero A, Rossetti R, Tonato M, Rambotti P, et al. (1989) Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64:1805-1811.
7. Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, and Wilkinson GR (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13:595-606.
8. Frost BM, Lonnerholm G, Koopmans P, Abrahamsson J, Behrendtz M, Castor A, Forestier E, Uges DR, and de Graaf SS (2003) Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. Acta Paediatr 92:551-557.
9. Goswami A, Macdonald TL, Hubbard C, Duffel MW, and Rosazza JP (1988) Leurosine biotransformations: an unusual ring-fission reaction catalyzed by peroxidase. Chem Res Toxicol 1:238-242.
10. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, and van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245-254.
11. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
12. Kamaluddin M, McNally P, Breatnach F, O'Marcaigh A, Webb D, O'Dell E, Scanlon P, Butler K, and O'Meara (2001)A potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Pediatr 90:1204-1207.
13. Kamdem LK, Streit F, Zanger UM, Brockmoller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
14. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins P, Daly A, Wrighton S, Hall S, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
15. Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, Heerema NA, Wimmer RS, Trigg ME, and Sather HN (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-833.
16. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, and Holt DW (2002) Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74:1486-1489.
17. McConn DJ, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
18. McCune J and Lindley C (1997) Appropriateness of maximum dose guidelines for vincristine. Am J Health Syst Pharm 54:1755-1758.
19. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, and Shen DD (2005) Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos 33:1074-1081.
20. Nair S, Eustace J, and Thuluvath P (2002) Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 359:287-293.
21. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 31:938-944.
22. Pollock B, DeBaun M, Camitta B, Shuster J, Ravindranath Y, Pullen D, Land V, Mahoney DJ, Lauer S, and Murphy S (2000) Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. J Clin Oncol 18:813-823.
23. Rahmani R and Zhou X (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17:269-281.
24. Rao KSPB, De Bruyn A, Trouet A, Verzele M, and Hannart J (1989) Proton NMR and carbon-13 NMR study of two vincristine derivatives at 300 MHz. J Bull Soc Chim Belg 98:125-132.
25. Sathiapalan RK and El-Solh H (2001) Enhanced vincristine neurotoxicity from drug interactions: case report and review of literature. Pediatr Hematol Oncol 18:543-546.
26. Shih PS and Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30:1491-1496.
27. Van den Berg H, Desai Z, Wilson R, Kennedy G, Bridges J, and Shanks R (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215-219.
28. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
29. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, and Wrighton SA (2002) Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metab Dispos 30:883-891.
30. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, and Gurney H (2004) CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 75:529-538.
31. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.
32. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, et al. (2004) Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 76:104-112.
33. Zhou X, Placidi M, and Rahmani R (1994) Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res 14:1017-1022.
34. Zhou X, Zhou-Pan X, Gauthier T, Placidi M, Maurel P, and Rahmani R (1993) Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol 45:853-861.
35. Zhou-Pan X, Seree E, Zhou X, Placidi M, Maurel P, Barra Y, and Rahmani R (1993) Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126.